AffloVest's Inventory Reset Is the Temporary Wrinkle in an Otherwise Strong Tactile Quarter

Double-digit lymphedema growth and record profitability overshadow an airway-clearance channel reset and a step-up in strategic tuck-ins.

TCMD · Earnings Call · 2026-08-10

Another strong quarter, with a familiar wrinkle

Tactile Systems delivered a Q2 that, on the surface, reads as business as usual: “We delivered another strong quarter of execution in Q2, highlighted by continued strength in our lymphedema business and meaningful profitability expansion.” — Sheri Dodd, Chief Executive Officer · 2026-08-10 Total revenue rose 9% to $85.7M, but the composition is the story. Lymphedema — the lymphedema business — grew 12%, while airway clearance revenue fell 7% as a handful of large DME partners worked through elevated inventory ahead of the next-generation AffloVest System launch. On a trailing-12-month basis, AffloVest is still up 32% y/y, so the pullback is a channel timing artifact, not end-market weakness.

Gross margin expanded 180 basis points to 76.3%, helping drive adjusted EBITDA up 49% to $11.4M. Management chose to hold full-year adjusted EBITDA guidance at $49-51M while raising revenue to $360-366M, a deliberate signal that the airway clearance dip is being absorbed rather than used as an excuse to raise the bottom line.

Airway clearance: temporary, but not drama-free

The AffloVest dynamic is precisely the kind of timing issue that can be confusing for investors.

From a dynamic standpoint, the not complicated -- in launching our next-gen kind of product, it really forces our partners to take a look at overall inventory.
Elaine Birkemeyer, Chief Financial Officer · 2026-08-10

CFO Elaine Birkemeyer went on to explain that a few larger partners had been carrying elevated inventory management dynamic inventory, leading them to postpone normal purchases until they burn through stock. The company now expects those ordering patterns to normalize in Q4. Guidance for airway clearance was trimmed to roughly flat for the year, but the end-market fundamentals appear intact. The next-gen product also brings connectivity and size adjustability, and the DME channel remains the primary route to market. This is not a competitive loss; it's a working-down of stock that happens whenever you refresh a platform.

Lymphedema: tailwinds and friction

The lymphedema strength rests on a mix of tailwinds and a new administrative hurdle. Medicare prior authorization requirements went live April 13, adding steps to order completion. Sheri Dodd acknowledged “a full quarter of experience now behind us, we expect the initial impacts of the implementation to moderate.” — Sheri Dodd, Chief Executive Officer · 2026-08-10 This follows the company's earlier framing — in May — when the team described the situation as an acceleration of in-process orders rather than a pull-forward. “What we did is we had patients whose orders were in process... a little bit of an acceleration.” — Sheri Louise Dodd, Chief Executive Officer · 2026-05-04 The Medicare NCD alignment is still giving Flexitouch adoption a tailwind, but the prior auth acts as a temporary drag on order flow. The company expects Q3 to show a bigger sequential step-up, much like last year, once the process matures.

Looking back, the Q4 2025 strength was already pointing to this momentum. As Sheri noted on the February call: “Really, what we're seeing in Q4 was multiple investments in people and processes and technology, all coming together that really enabled the company to outperform expectations.” — Sheri Dodd · 2026-02-18 Those investments are now translating into the lymphedema growth we're seeing today.

Broadening the care continuum

Beyond the quarter, Tactile is extending its franchise beyond pneumatic pumps. The July exclusive distribution agreement with ElastiMed for MyoSleeve gives the company a non-pneumatic compression option for the VA and Department of Defense channels. “So, I'll answer your last question first. So, we do see MyoSleeve as an incremental growth contributor within the VA channel over time, but our current guidance does not assume any material contribution from MyoSleeve.” — Elaine Birkemeyer, Chief Financial Officer · 2026-08-10 That discipline is consistent with how the company approaches tuck-ins: leverage existing field relationships and don't count the chicken before it hatches.

Meanwhile, LymphaTech — the 3D imaging acquisition — is now being positioned as a diagnostic aid with an FDA submission targeted for 2027 and a Category III CPT code workstream. This taps into the company's ambition to address the approximately 20 million undiagnosed U.S. lymphedema patients. The care continuum is becoming a bigger part of how management frames growth.

Head-and-neck lymphedema clinical evidence is another frontier. The 6-month manuscript, published in a peer-reviewed journal, hasn't yet moved the needle on commercial market access; payor policy changes are expected to happen over 2026-2027. But the data gives the company a new tool in its clinical evidence arsenal.

A patient balance sheet, widening optionality

Financially, Tactile remains in a strong position: cash of $69.9M, no debt, and gross margins trending toward 76-76.5% for the year. Net cash fell from $83M to $75M at the end of Q2, largely reflecting upfront ElastiMed-related payments and share repurchases. But excluding strategic uses of cash, operating cash flow was positive. The focus on gross margin and disciplined OpEx has translated into improving profitability even as the company invests in AI and order operations. The inventory-based revenue dip in AffloVest may feel like a step back, but it is also a reminder that the company has the balance sheet to ride out such blips and continue investing in the long-term story.